text_1: 预后 因素 证明 , SOLO1 试验 中 患者 的 疾病 进展 或 死亡 风险 较 低 , 因为 SOLO1 试验 的 患者 与 PRIMA 试验 相比 , Ⅲ 期 疾病 患者 较 多 ( 83% vs . 65% ) , 而 接受 新 辅助 化疗 的 患者 较 少 ( 35% vs . 67% ) .
  
text_2: patients in SOLO1 were at lower risk for disease progression or death as evidenced by prognostic factors , since more patients in SOLO1 than in PRIMA had stage III disease ( 83 % vs. 65 % ) and fewer received neoadjuvant chemotherapy ( 35 % vs. 67 % ) .
  